Scientists at the University of California, San Francisco (UCSF) have uncovered a fundamental biological mechanism that explains how pancreatic cancer cells successfully colonize different organs during metastasis. The study, which identifies a protein known as PCSK9 as a master regulator of this process, offers a new perspective on how one of the world’s most lethal cancers adapts to vastly different physiological environments. By understanding how these cells transition between the nutrient-rich environment of the liver and the oxygen-heavy atmosphere of the lungs, researchers believe they have found a potential vulnerability in a disease that has long been considered notoriously resistant to conventional therapies.
The findings, published on May 21 in the prestigious journal Nature, address one of the most challenging aspects of oncology: the ability of cancer cells to thrive in environments that are as distinct to a cell as the ocean and the desert are to terrestrial animals. In the case of pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer, this adaptability is particularly deadly. Often, the spread of cancer cells to distant organs like the lungs or the liver produces the very first symptoms a patient might notice. Unfortunately, by the time these symptoms manifest, the cancer has typically spread out of control, making surgical intervention difficult and significantly reducing the efficacy of existing treatments.
The research team, led by senior author Rushika Perera, PhD, who serves as the Deborah Cowan Endowed Associate Professor of Anatomy at UCSF, sought to understand the metabolic "logic" behind this organ-specific colonization. To do so, they turned to a wealth of existing data from MetMap, a comprehensive project hosted by the Broad Institute, an independent research organization. MetMap serves as a repository of information regarding the metastatic potential of various cancer cell lines, allowing scientists to track where specific cells are likely to travel and survive within the body. By analyzing this data, the UCSF team identified specific pancreatic cancer cell lines that demonstrated a clear preference for either the lung or the liver.
Once these cell lines were categorized by their destination preference, the researchers performed a deep genomic analysis to uncover the differences that allowed these cells to choose—and survive in—one organ over the other. Their investigation led them to a protein called PCSK9 (Proprotein Convertase Subtilisin/Kexin type 9). While PCSK9 is well-known in the medical community for its role in regulating cholesterol levels in the blood, its role as a switch for cancer metastasis represents a significant shift in how scientists view the protein’s function.
The study revealed that PCSK9 acts as a metabolic thermostat, controlling how pancreatic cancer cells obtain the cholesterol they need to build their outer membranes and fuel their growth. The availability of cholesterol varies wildly depending on the organ. The liver, for example, is the body’s primary factory for cholesterol, making it a target-rich environment for cancer cells. The lungs, conversely, are cholesterol-poor but high in oxygen, presenting a different set of survival challenges.
The researchers found that when PCSK9 levels are low, pancreatic cancer cells are programmed to "scavenge" or consume nearby cholesterol from their immediate surroundings. Because the liver is naturally abundant in cholesterol, these low-PCSK9 cells find it to be an ideal environment for colonization. In this scenario, the cancer cells do not need to expend energy producing their own lipids; they simply absorb what is readily available in the hepatic tissue. This metabolic efficiency allows the tumor to establish itself quickly within the liver, often leading to the rapid progression of the disease in that organ.
However, the story changes when PCSK9 levels are high. In these instances, the cancer cells undergo a metabolic transformation. Instead of relying on external sources, high-PCSK9 cells begin to produce their own cholesterol internally. This self-sufficiency is a critical adaptation for survival in the lungs, where external cholesterol is scarce. Furthermore, the researchers discovered that the high levels of PCSK9 also trigger the production of specific molecules that protect the cancer cells from oxidative stress. Because the lungs are an environment defined by high oxygen exposure, cells are at constant risk of damage from reactive oxygen species. The metabolic shift orchestrated by PCSK9 provides a "perfect adaptation" for survival in the pulmonary environment, shielding the cancer cells from the very oxygen that sustains the rest of the body.
To test the strength of this discovery, the UCSF team conducted a series of experiments to see if they could manipulate the destination of the cancer. They took pancreatic cancer cells that were genetically predisposed to colonize the liver—cells that naturally expressed low levels of PCSK9—and forced them to express the protein at high levels. The results were striking. Instead of heading for the cholesterol-rich liver as they normally would, the modified cells made a literal and metaphorical detour, successfully colonizing the lungs instead. This confirmed that PCSK9 is not merely a marker of where a cell might go, but a primary driver of the metastatic process itself.
"Cancers persist by adapting to live in new tissues and organs, and we found that pancreatic tumors use PCSK9 to adapt as they spread," explained Dr. Perera. Her observations highlight a critical shift in cancer research: moving beyond looking at what a cancer cell is and focusing instead on what it does to survive in a new home. By identifying the metabolic tools these cells use to survive in hostile environments, researchers can begin to look for ways to take those tools away. "It opens the door to fighting metastatic cancer growth by manipulating how cells acquire their cholesterol," Perera added.
The implications of this study are profound for the future of pancreatic cancer treatment. Because pancreatic cancer is so often diagnosed only after it has reached the metastatic stage, understanding the mechanisms of spread is essential for developing therapies that can slow or stop the disease. If doctors can interfere with the PCSK9-driven metabolic switch, they might be able to prevent the cancer from adapting to new organs, or perhaps make the environments of the lungs and liver inhospitable to the invading cells.
This research also adds to a growing body of evidence suggesting that the metabolic flexibility of cancer cells is one of their greatest strengths. While traditional chemotherapy often targets the cell’s ability to divide, metabolic therapies like those suggested by this study would target the cell’s ability to "eat" and protect itself. By cutting off the supply of cholesterol or stripping away the oxidative protection provided by PCSK9, new treatments could potentially starve or weaken metastatic tumors in a way that current drugs cannot.
The study was a collaborative effort, utilizing the resources of the Broad Institute and drawing on the expertise of various scientific disciplines. The complexity of the work—combining genomic analysis, metabolic profiling, and experimental oncology—required significant support from major scientific institutions. Funding for the study was provided in part by the National Institutes of Health (NIH), the National Science Foundation (NSF), and the American Association for Cancer Research (AACR).
As the scientific community continues to digest the findings published in Nature, the focus will likely turn toward how this knowledge can be translated into clinical practice. While the study primarily focused on the fundamental biology of how PCSK9 functions in pancreatic cancer, the fact that PCSK9 is already a target in other areas of medicine provides a potential head start for future drug development. The ability to redirect or stop the spread of such a devastating disease remains the ultimate goal for Dr. Perera and her colleagues at UCSF.
For now, the discovery serves as a vital piece of the puzzle in the fight against pancreatic cancer. It clarifies why the disease is so adept at moving through the body and provides a clear molecular target for researchers to pursue. By shedding light on the metabolic "survival kits" that cancer cells carry with them as they travel from the pancreas to the lungs or liver, this study offers a new roadmap for intervention in a disease where time and effective treatment options are often in short supply.
